PressOctober 30, 2020 MindMed Closes Upsized Financing of CAD $28.75m With Strong Institutional Demand for Psychedelic Medicines
PressOctober 29, 2020 Better Plant Receives Health Canada Approval for Plant-Based Antiseptic Skin Ointment
PressOctober 27, 2020 ATAI Life Sciences Announces Neuronasal Completes Pilot Study, Receives IND Clearance to Continue into Phase I Trials of mTBI Therapeutic
PressOctober 26, 2020 Field Trip Health Ltd. : Continues Expansion With Psychedelic-Enhanced Therapy Center in Chicago
InterviewsOctober 23, 2020 Mr. Psychedelic Law: Addressing Psychedelic Decriminalization on a City-by-City Basis
PressOctober 22, 2020 Numinus First Canadian Public Company to Complete Legal Harvest of Psilocybe Mushrooms
PressOctober 21, 2020 Pharmather Files for FDA Orphan Drug Designation for Ketamine in Parkinson’s Disease
PressOctober 20, 2020 Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds
PressOctober 19, 2020 Cybin and Clarmin Announce Closing of CDN$45 Million Oversubscribed Private Placement and Provide Update on RTO
PressOctober 19, 2020 MindMed Files Preliminary Prospectus In Connection With Bought Deal Equity Financing
PressOctober 16, 2020 Universal Ibogaine Retains Westmount Park Investments for Corporate Financial Advisory Services
PressOctober 15, 2020 Pharmather Announces Exclusive License Agreement with the University of Arizona for the Commercialization of Ketamine in the Treatment of Parkinson’s Disease
PressOctober 15, 2020 Silo Pharma, Inc. (SILO) Announces Successful Uplisting To the OTCQB Venture Market
PressOctober 14, 2020 Study: MDMA-Assisted Psychotherapy Will Be More Cost-Effective than Other Treatments for PTSD
InterviewsOctober 14, 2020 Psilera Bioscience: Developing the Next Generation of Safer, Targeted Psychedelic Therapies
PressOctober 14, 2020 Osmind Raises $2M Seed Round to Revolutionize Mental Health by Empowering Mental Health Patients, Clinicians, and Researchers
